Table 1.
Summary of protein kinase inhibitors suppressing mammosphere formation
| Number | Name | Targets | Inhibitory activity | Number | Name | Targets | Inhibitory activity |
|---|---|---|---|---|---|---|---|
| B1 | PD-98059 | MEK | Negative | C1 | Tyrphostin 46 | EGFRK, PDGFRK | Negative |
| B2 | U-0126 | MEK | Negative | C2 | Tyrphostin 47 | EGFRK | Negative |
| B3 | SB-203580 | p38 MAPK | Negative | C3 | Tyrphostin 51 | EGFRK | Negative |
| B4 | H-7 2HCl | PKA, PKG, MLCK, PKC | Negative | C4 | Tyrphostin 1 | Negative control for tyrosine kinase | Negative |
| B5 | H-9 HCl | PKA, PKG, MLCK, PKC | Negative | C5 | Tyrphostin AG 1288 | Tyrosine kinases | Negative |
| B6 | Staurosporine | Pan-specific | Negative | C6 | Tyrphostin AG 1478 | EGFRK | Positive |
| B7 | AG-494 | EGFRK, PDGFRK | Negative | C7 | Tyrphostin AG1295 | Tyrosine kinases | Negative |
| B8 | AG-825 | HER1-2 | Negative | C8 | Tyrphostin 9 | PDGFRK | Negative |
| B9 | Lavendustin A | EGFRK | Negative | C9 | Hydroxy-2-naphthalenyl methylphosphonic acid | IRK | Negative |
| B10 | RG-1462 | EGFRK | Negative | C10 | PKC-412 | PKC inhibitor | Negative |
| B11 | Tyrphostin 23 | EGFRK | Negative | C11 | Piceatannol | Syk | negative |
| B12 | Tyrphostin 25 | EGFRK | Negative | C12 | PP1 | Src family | Negative |
| D1 | AG-490 | JAK-2 | Negative | E1 | HA-1004 2HCl | PKA, PKG | Negative |
| D2 | AG-126 | IRAK | Negative | E2 | HA-1077 2HCl | PKA, PKG | Negative |
| D3 | AG-370 | PDGFRK | Negative | E3 | 2-Hydroxy-5-(2,5-dihydroxy benzyl amino) benzoic acid | EGFRK, CaMK II | Negative |
| D4 | AG-879 | NGFRK | Negative | E4 | KN-62 | CaMK II | Positive |
| D5 | LY 294002 | PI 3-K | Negative | E5 | KN-93 | CaMK II | Positive |
| D6 | Wortmannin | PI 3-K | Negative | E6 | ML-7 HCl | MLCK | Positive |
| D7 | GF 109203X | PKC | Negative | E7 | ML-9 HCl | MLCK | Negative |
| D8 | Hypericin | PKC | Negative | E8 | 2-Aminopurine | p58 PITSLRE beta1 | Negative |
| D9 | Ro 31-8220 mesylate | PKC | Positive | E9 | N9-isopropyl-olomoucine | CDK | Negative |
| D10 | d-Erythro-Sphingosine | PKC | Positive | E10 | Olomoucine | CDK | Negative |
| D11 | H-89 2HCl | PKA, | Negative | E11 | Iso-olomoucine | Negative control for olomoucine | Negative |
| D12 | H-8 | PKA, PKG | Negative | E12 | Roscovitine | CDK | Negative |
| F1 | 5-Iodotubericidin | ERK2, CK1, CK2 | Positive | G1 | Erbstatin analog | EGFRK | Negative |
| F2 | LFM-A13 | BTK | Negative | G2 | Quercetin 2H2O | PI 3-K | Negative |
| F3 | SB-202190 | p38 MAPK | Negative | G3 | SU1498 | Flk1 | Negative |
| F4 | PP2 | Src family | Negative | G4 | ZM 449829 | JAK-3 | Positive |
| F5 | ZM 336372 | cRAF | Negative | G5 | BAY 11-7082 | IKK pathway | Positive |
| F6 | SU 4312 | Flk1 | Negative | G6 | 5,6-dichloro-1-β-d-ribofuranosylbenzimidazole | CK II | Negative |
| F7 | AG-1296 | PDGFRK | Negative | G7 | 2,2′,3,3′,4,4′-Hexahydroxy-1,1′-biphenyl-6,6′dimethanol dimethyl ether | PKC alpha, PKC gamma | Negative |
| F8 | GW 5074 | cRAF | Negative | G8 | SP 600125 | JNK | Negative |
| F9 | Palmitoyl-d l-carnitine | PKC | Negative | G9 | Indirubin | GSK-3beta, CDK5 | Negative |
| F10 | Rottlerin | PKC delta | Positive | G10 | Indirubin-3′-monooxime | GSK-3beta | Positive |
| F11 | Genistein | Tyrosine kinases | Negative | G11 | Y-27632 2HCl | ROCK | Negative |
| F12 | Daidzein | Negative control for genistein | Negative | G12 | Kenpaullone | GSK-3beta | Negative |
| H2 | Triciribine | Akt signaling | Negative | H6 | Apigenin | CK-II | Negative |
| H3 | BML-257 | Akt | Negative | H7 | BML-265 | EGFRK | Negative |
| H4 | SC-514 | IKK2 | Negative | H8 | Rapamycin | mTOR | Negative |
| H5 | BML-259 | Cdk5/p25 | Negative |